NCT04061980 is a phase II clinical trial combining a MAPK inhibitor and a PD-1 inhibitor [38]; this study aims to assess the efficacy and safety of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) with or without nivolumab (anti-PD-1 antibody) in patients with BRAF V600-mutated metastatic and refractory thyroid cancer not responsive to radioiodine treatment (Table 10) [38]. Here, BRAF is linked to thyroid cancer.